This is the authors' abstract. We don't add key points for this paper.
Background Multiple myeloma (MM) is an incurable plasma cell malignancy with increasing global incidence. Chimeric antigen receptor (CAR) T-cell therapy targeting BCMA has shown efficacy in relapsed or refractory MM, but it faces resistance due to antigen loss and the tumor microenvironment. Bispecific T-cell engaging (BITE) antibodies also encounter clinical challenges, including short half-lives requiring continuous infusion and potential toxicities. Methods To address these issues, we developed a lentiviral system to engineer T cells that secrete αB7-H3-αCD3 bispecific engager molecules (αB7-H3-αCD3 ENG-T cells). We evaluated their effectiveness against MM cells with varying B7-H3 expression levels, from B7-H3 neg to B7-H3 high . Results The αB7-H3-αCD3 ENG-T cells demonstrated significant anti-tumor activity against MM cell lines expressing B7-H3. SupT-1 cells (B7-H3 neg ) served as controls and exhibited minimal cytotoxicity from αB7-H3-αCD3 ENG T cells. In contrast, these engineered T cells showed dose-dependent killing of B7-H3-expressing MM cells: NCI-H929 (B7-H3 low ), L-363 (B7-H3 medium ), and KMS-12-PE (B7-H3 high ). For NCI-H929 cells, cytotoxicity reached 38.5 ± 7.4% ( p = 0.0212) and 54.0 ± 9.2% ( p = 0.0317) at effector-to-target (E:T) ratios of 5:1 and 10:1, respectively. Against L-363 cells, cytotoxicity was 56.6 ± 3.2% ( p < 0.0001) and 71.4 ± 5.2% ( p = 0.0002) at E:T ratios of 5:1 and 10:1, respectively. For KMS-12-PE cells, significant cytotoxic effects were observed even at an E:T ratio of 1:1, with 27.2 ± 3.7% ( p = 0.0004), 44.4 ± 3.7% ( p < 0.0001), and 68.6 ± 9.2% ( p = 0.0004) cytotoxicity at E:T ratios of 1:1, 5:1, and 10:1, respectively. Conclusions These results indicate that αB7-H3-αCD3 ENG T cells could be a promising therapy for B7-H3-positive MM. They may enhance current MM treatments and improve overall outcomes. Additional preclinical and clinical research is required to fully assess their therapeutic potential.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Rujirachaivej et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: